Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

Fineline Cube Feb 11, 2026
Company Deals Medical Device

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

Fineline Cube Feb 11, 2026
Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Fineline Cube Feb 11, 2026
Company Deals

uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases

Fineline Cube Feb 11, 2026
Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Fineline Cube Feb 11, 2026
Company Drug

Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication

Fineline Cube Feb 11, 2026
Company Deals

Shandong Buchang Pharmaceuticals Terminates Agreement with NOVAST Laboratories

Fineline Cube Dec 27, 2024

China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) has announced the termination of the development,...

Company Drug

Chia Tai Tianqing’s Benmelstobart and Anlotinib Combo Meets Primary Endpoint in Phase III Study

Fineline Cube Dec 27, 2024

China-based Chia Tai Tianqing Pharmaceutical, a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177), has announced...

Company Drug

China Isotope & Radiation Corporation’s [18F] Piramide Receives NMPA Clinical Trial Approval

Fineline Cube Dec 27, 2024

On December 24, 2024, China Isotope & Radiation Corporation (HKG: 1763) announced that its subsidiary,...

Company Drug

Hybio Pharmaceutical Receives US FDA Approval for Biosimilar Victoza (Liraglutide)

Fineline Cube Dec 26, 2024

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving official approval from the US...

Company Drug

Shanxi C&Y Pharmaceutical Initiates Clinical Study for Generic Ferric Maltol with NMPA Approval

Fineline Cube Dec 26, 2024

China’s Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254) has announced the initiation of a...

Company Drug

Boji Medical Technology Receives NMPA Approval for TBA Clinical Study in Drug-Resistant Tuberculosis

Fineline Cube Dec 26, 2024

China-based Clinical Research Organization (CRO) Boji Medical Technology Co., Ltd. (SHE: 300404) has announced receiving...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Prostate Cancer and Solid Tumor Clinical Trials

Fineline Cube Dec 26, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...

Company Drug

Sichuan Biokin’s BL-M08D1 and CSPC’s SYS6010 Eye Breakthrough Therapy Designations in China

Fineline Cube Dec 26, 2024

The China’s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical...

Company Drug

CDE Indicates Priority Review for Boehringer Ingelheim’s Zongertinib and Peers

Fineline Cube Dec 26, 2024

The China’s Center for Drug Evaluation (CDE) website has indicated that several drugs, including German...

Company Drug

Zelgen Biopharmaceuticals’ ZG005 Gets NMPA Green Light for Solid Tumor and Lymphoma Clinical Trial

Fineline Cube Dec 26, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical approval from the National...

Company

Western Chongqing Southern Sichuan Precision Medicine Center Digital Platform Launches in Rongchang District

Fineline Cube Dec 26, 2024

On December 24, the Western Chongqing Southern Sichuan Precision Medicine Center Digital Information Platform was...

Company Drug

ProteLight Pharma’s Peceleganan (PL-5) Accepted for Review by China’s CDE

Fineline Cube Dec 26, 2024

China’s Center for Drug Evaluation (CDE) website has indicated that a market filing by local...

Company Deals

Innovent Biologics Partners with Suzhou ForLong to Explore Sintilimab and FL115 Combination in Solid Tumors

Fineline Cube Dec 26, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has announced a clinical study and supply agreement with...

Company Deals

Zhejiang Huahai Pharmaceutical’s Subsidiary Huaota Bio Secures $27.4 Million Investment

Fineline Cube Dec 26, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that its macromolecular drug-focused subsidiary, Shanghai...

Company Drug

Bristol-Myers Squibb’s Sotyktu Meets Primary Endpoints in POETYK PsA Studies

Fineline Cube Dec 25, 2024

US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from the pivotal...

Company Deals

Bio-Thera Solutions Enters Licensing Agreement with Tabuk Pharmaceutical for BAT2206 in Saudi Arabia

Fineline Cube Dec 25, 2024

China-based Bio-Thera Solutions (SHA: 688177) has announced a licensing agreement with Tabuk Pharmaceutical Manufacturing Company,...

Company Deals

Achilles Therapeutics and AstraZeneca Seal $12 Billion Deal for TRACERx NSCLC Study Data

Fineline Cube Dec 25, 2024

UK-based Achilles Therapeutics plc has announced a landmark deal worth USD 12 billion with AstraZeneca...

Company Drug

Nuvation Bio’s Taletrectinib NDA for ROS1+ NSCLC Receives FDA Priority Review

Fineline Cube Dec 25, 2024

US-based Nuvation Bio Inc. (NYSE: NUVB) has announced that the New Drug Application (NDA) for...

Company Drug

Shanghai Henlius Biotech Initiates Patient Dosing in Global Phase III ELAINE-3 Study for Lasofoxifene

Fineline Cube Dec 25, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Medical Device

RaysightMed’s AngioQFA 100 Receives NMPA Approval for Coronary Artery Function Measurement

Fineline Cube Dec 25, 2024

China-based RaysightMed Co., Ltd has announced that it has received marketing approval from the National...

Posts pagination

1 … 196 197 198 … 623

Recent updates

  • Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal
  • Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care
  • SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer
  • Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III
  • Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

Company Deals Medical Device

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.